title: Pharmacologic treatment strategies in children with type 2 diabetes mellitus.
abstract: We treated 80 obese and 28 nonobese children diagnosed as having type 2 diabetes mellitus (T2DM). Among these patients, 26 obese and 23 nonobese children were assigned to pharmacologic therapies during the course of diabetes. Pharmacologic therapies were started if the HbA1c (NGSP) value exceeded 7.0% despite dietary and exercise management. For the 26 obese patients, metformin alone or in combination with an additional medication was frequently used. Only 2 patients independently received sulfonylureas (SUs) in the form of glimepiride. In addition, 9 patients were treated with basal insulin supported with oral hypoglycemic drugs (OHDs) or biphasic premix insulin. On the other hand, the 23 nonobese patients were frequently treated with insulin alone or in combination with an additional medication followed by SUs. The nonobese patients tended to require pharmacologic therapies, in particular insulin, at an earlier stage of diabetes as compared with the obese patients. New antidiabetic drugs, DPP-4 inhibitors and GLP-1 receptor agonists, seemed to exert positive effects on glycemic control without occurrence of hypoglycemic episodes in some patients regardless of the type of diabetes. These results suggest that pharmacologic treatment strategies in childhood T2DM should be tailored to individual patient characteristics.
authors: Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan.
authors: Tatsuhiko
authors: T
authors: Urakami
authors: Remi
authors: R
authors: Kuwabara
authors: Masako
authors: M
authors: Habu
authors: Ayako
authors: A
authors: Yoshida
authors: Misako
authors: M
authors: Okuno
authors: Junichi
authors: J
authors: Suzuki
authors: Shori
authors: S
authors: Takahashi
authors: Hideo
authors: H
authors: Mugishima
keywords: nonobese; obese; pharmacologic therapies; type 2 diabetes
references: Diabetes Care. 2005 Aug;28(8):1876-81
references: 16043726
references: Diabetes Res Clin Pract. 2008 Aug;81(2):161-8
references: 18495285
references: JAMA. 2007 Jul 11;298(2):194-206
references: 17622601
references: Pediatr Int. 2003 Oct;45(5):642-6
references: 14521550
references: Diabetes Care. 2004 Apr;27(4):998-1010
references: 15047665
references: Pediatr Res. 2007 Feb;61(2):141-5
references: 17237712
references: Clin Pediatr Endocrinol. 2005;14(1):1-9
references: 24790303
references: Pediatr Diabetes. 2009 Sep;10 Suppl 12:17-32
references: 19754615
references: Diabetes Care. 2012 Jun;35(6):1364-79
references: 22517736
references: Lancet. 2008 Oct 4;372(9645):1240-50
references: 18782641
references: Clin Pediatr Endocrinol. 2005;14(2):65-75
references: 24790313
references: Diabetes Metab Res Rev. 2007 Mar;23(3):234-8
references: 16952202
references: Diabetologia. 2007 Sep;50(9):1900-1909
references: 17632702
references: J Diabetes Investig. 2010 Aug 2;1(4):123-33
references: 24843420
references: Pediatr Endocrinol Rev. 2005 Sep;3(1):33-9
references: 16369211
references: Diabetes Care. 2007 Apr;30(4):790-4
references: 17392540
references: Pediatr Diabetes. 2007 Dec;8 Suppl 9:7-15
references: 17991128
references: Diabetes Res Clin Pract. 2003 Jul;61(1):13-9
references: 12849919
references: Ann Pharmacother. 1998 Oct;32(10):1044-52
references: 9793597